Sanjay Rakhade
Executive Director - Medical & Clinical Development Alexion Pharmaceuticals
Seminars
Wednesday 22nd July 2026
Panel Discussion: Positioning Novel Mechanisms in the Myasthenia Gravis Market to Deliver Differentiated Patient Benefit
9:00 am
- Comparing how FcRn inhibition, complement blockade, B-cell depletion and CAR-T differ mechanistically and where each may sit best based on disease biology
- Examining how mechanistic sequencing could address patients exposed to prior lines of therapy without clear biomarkerguidance
- Identifying emerging strategies for treating MG patients who fail FcRn inhibition, IgG degraders or complement therapies
- Gain insight into how to position assets in a saturated market while addressing inadequate responders and future curative ambition
Thursday 23rd July 2026
Fireside Chat: Big Pharma Perspective on Emerging Commercial Opportunity to Investigate Existing Autoimmune Therapeutics within the Myasthenia Gravis & Peripheral Neuropathies Space
3:00 pm
- Evaluating MG as a high-growth yet increasingly oversaturated market, recognising that multiple FcRn and C5 inhibitors show comparable aggregate efficacy but compete for a finite rare-disease population
- Identifying CIDP and MMN as commercially compelling but biologically underdefined opportunities, due to uncertainty around immunologic origin, incomplete real-world efficacy and unclear prevalence
- Balancing chronic suppression models against emerging immune-reset approaches, comparing repeated FcRn/complement administration with upstream
- B-cell or CAR-T interventions to inform long-term investment decisions focused on durable remission and defensible market positioning
